Deerfield Management Company, L.P. (Series C) Halozyme Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2024 May 15, 2024	BUY	$33.68 - $41.95 $371,894 - $463,211	11,042 New	11,042 $449,000

Others Institutions Holding HALO

# of Institutions

542

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

Black Rock Inc. New York, NY

17.6M
Shares

$930 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

12.9M
Shares

$681 Million
0.01% of portfolio
State Street Corp Boston, MA

6.63M
Shares

$350 Million
0.02% of portfolio
Snyder Capital Management L P San Francisco, CA

4.06M
Shares

$215 Million
5.07% of portfolio
Alliancebernstein L.P. New York, NY

3.41M
Shares

$180 Million
0.07% of portfolio

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.35B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account